Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease'
Stay updated with breaking news from Christoph Ganss. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RHEACELL announces "First Patient In": EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
Heidelberg, November 9, 2022. The biopharmaceutical company RHEACELL, which specializes in stem cells, was honored on October 24 by the organization 'Dystrophic Epidermolysis Bullosa Research Association of America' (debra) with the 'Partners in Progress Award'.
HEIDELBERG, GERMANY / ACCESSWIRE / October 19, 2021 / Heidelberg-based biopharmaceutical company is conducting a follow-up study with highly purified stem cells (AMESANAR (R) ) for the treatment of previously
Germany Approves Novel Cell Therapy Extracted from Skin - read this article along with other careers information, tips and advice on BioSpace